AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23316787 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning sessions
Number of subjects: 201
Study 23316787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three components
Number of subjects: 201
Study 23316787 — intervention group
Group type: COMPARATOR
Intervention: Interest circle calls
Number of subjects: 201
Study 23548251 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 μg per vaginally at 24 hours after mifepristone
Number of subjects: 200
Study 23548251 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone and misoprostol combination at 48 hours interval
Number of subjects: 200
Study 19488583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 42
Study 19488583 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control)
Number of subjects: 42
Study 16796988 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture approximation of Camper's fascia
Number of subjects: 222
Study 16796988 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage of the subcutaneous space
Number of subjects: 222
Study 16796988 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 222
Study 12616322 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)FDG-PET
Number of subjects: 17
Study 12616322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (18)FDG-PET and BS
Number of subjects: 17
Study 12616322 — intervention group
Group type: EXPERIMENTAL
Intervention: SPET LS images
Number of subjects: 17
Study 12616322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of planar BS and LS
Number of subjects: 17
Study 10661480 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily with or without betaine 4 g per day for 12 weeks, followed by 1 or 5 mg of folic acid thereafter for 40 weeks.
Number of subjects: 54
Study 10661480 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment for hyperhomocysteinemia.
Number of subjects: 54
Study 9288665 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 348
Study 9288665 — intervention group
Group type: COMPARATOR
Intervention: Control (PRE phase)
Number of subjects: 348
Study 7682932 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h free-field exposure to intermittent trains of 89 dB low frequency tones
Number of subjects: 28
Study 7682932 — intervention group
Group type: EXPERIMENTAL
Intervention: tones presented through headphones
Number of subjects: 28
Study 7682932 — intervention group
Group type: EXPERIMENTAL
Intervention: target-induced ERSPs
Number of subjects: 28
Study 3552397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre optic transillumination (FOTI)
Number of subjects: 3003
Study 31424631 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm trials
Number of subjects: 0
Study 31424631 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 29465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-containing agent (GCA) application
Number of subjects: 17
Study 29465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W/cm2, 10 Hz) irradiation
Number of subjects: 17
Study 29465059 — intervention group
Group type: EXPERIMENTAL
Intervention: GCA application followed by Nd:YAG laser irradiation
Number of subjects: 17
Study 29465059 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (0.25 W/cm2, 20 Hz) irradiation
Number of subjects: 17
Study 29465059 — intervention group
Group type: EXPERIMENTAL
Intervention: GCA application followed by Er,Cr:YSGG laser irradiation
Number of subjects: 17
Study 27764692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 76
Study 27764692 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 76
Study 25354985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene education and individual feedback
Number of subjects: 24
Study 24074810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTCZ) with low-dose cortisol
Number of subjects: 20
Study 24074810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTCZ) with high-dose cortisol
Number of subjects: 20
Study 24074810 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 21959825 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide + Losartan 50 mg/day
Number of subjects: 60
Study 21959825 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 60
Study 21959825 — intervention group
Group type: COMPARATOR
Intervention: Thiazide 50 mg/day
Number of subjects: 60
Study 18245696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubing containing diethylhexyl phthalate (Group A)
Number of subjects: 16
Study 18245696 — intervention group
Group type: COMPARATOR
Intervention: Tubing without diethylhexyl phthalate (Group B)
Number of subjects: 16
Study 16841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 0
Study 16841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0
Study 16841795 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea and busulfan
Number of subjects: 0
Study 12638027 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d for 3 months
Number of subjects: 54
Study 12638027 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 54
Study 10638876 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 135
Study 10638876 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 135
Study 10638876 — intervention group
Group type: COMPARATOR
Intervention: Control (Social Work)
Number of subjects: 135
Study 8667171 — intervention group
Group type: EXPERIMENTAL
Intervention: Repressers
Number of subjects: 0
Study 8667171 — intervention group
Group type: COMPARATOR
Intervention: Nonrepressers
Number of subjects: 0
Study 1416115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative normovolemic hemodilution (PNH)
Number of subjects: 20
Study 1416115 — intervention group
Group type: COMPARATOR
Intervention: No PNH (Control)
Number of subjects: 20
Study 1416115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic clamping
Number of subjects: 20
Study 3917264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms b.i.d. for 5 days
Number of subjects: 24
Study 3917264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 7 micrograms b.i.d. for 5 days
Number of subjects: 24
Study 3917264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30563934 — intervention group
Group type: EXPERIMENTAL
Intervention: Afuresertib at 125 mg/day with intravenous paclitaxel (175 mg/m2) and carboplatin (AUC5) every 3 weeks for six cycles followed by maintenance afuresertib at 125 mg/day
Number of subjects: 59
Study 27706120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray containing liposomes, vitamins A and E (experimental arm group I)
Number of subjects: 40
Study 27706120 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (sodium chloride 0.9%) (control arm group II)
Number of subjects: 40
Study 26525391 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (use of five or more drugs)
Number of subjects: 4056
Study 26525391 — intervention group
Group type: COMPARATOR
Intervention: No polypharmacy (less than five drugs)
Number of subjects: 4056
Study 26525391 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 4056
Study 26525391 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of drugs
Number of subjects: 4056
Study 25132863 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of endotracheal tube A
Number of subjects: 6
Study 25132863 — intervention group
Group type: COMPARATOR
Intervention: Type of endotracheal tube B
Number of subjects: 6
Study 22607295 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin salve treatment
Number of subjects: 23
Study 19641054 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 300 mg administered perioperatively, 12 hours apart.
Number of subjects: 0
Study 19641054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 0
Study 17620739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 20 treatments at 2.0 ATA for 90 minutes
Number of subjects: 6
Study 16305082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) stimulation for 8 hours/day starting at day 10 after surgery
Number of subjects: 30
Study 16305082 — intervention group
Group type: COMPARATOR
Intervention: Non-stimulated sites
Number of subjects: 30
Study 16861258 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (2.2 ml) heavy with clonidine (75 microg) in 0.5 ml normal saline 0.9% (BC)
Number of subjects: 106
Study 16861258 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5% (2.2 ml) heavy with 0.5 ml normal saline 0.9% (B)
Number of subjects: 106
Study 10577295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/d)
Number of subjects: 212
Study 10577295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 8893536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (PR)
Number of subjects: 72
Study 8893536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 72
Study 2049311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (10 mg daily for six weeks, then alternating fortnights for 12 weeks) + Interferon-alpha 2b (2 x 10(6) U/m2 three times weekly for 18 weeks)
Number of subjects: 124
Study 2049311 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Interferon-alpha 2b
Number of subjects: 124
Study 2049311 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil alone
Number of subjects: 124
Study 6301364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (250 mg, single intramuscular dose)
Number of subjects: 51
Study 6301364 — intervention group
Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (4.8 X 10(6) U, two intramuscular doses)
Number of subjects: 51
Study 27091833 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 134
Study 27091833 — intervention group
Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 134
Study 30466850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon-based pulmonary vein isolation (PVI)
Number of subjects: 101
Study 26461925 — intervention group
Group type: COMPARATOR
Intervention: Activity group
Number of subjects: 36
Study 25150607 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 0
Study 25150607 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation with pressure support (P-SIMV)
Number of subjects: 0
Study 22309847 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available pressure relieving and thermally insulating insole
Number of subjects: 140
Study 22309847 — intervention group
Group type: COMPARATOR
Intervention: Sham insole with no cushioning or thermal properties
Number of subjects: 140
Study 20808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of aspirin (≥ 4 times/month)
Number of subjects: 42393
Study 20808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy use of combined aspirin and ibuprofen (≥ 2 times/day) in males
Number of subjects: 42393
Study 20808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of NSAIDs in females with BMI <25
Number of subjects: 42393
Study 20808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of ibuprofen
Number of subjects: 42393
Study 20808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 70-74 years
Number of subjects: 42393
Study 17950096 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 21
Study 17950096 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg + amlodipine 5 mg
Number of subjects: 21
Study 17950096 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 21
Study 15630735 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1902
Study 15630735 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 1902
Study 12241530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1.5 g daily in three doses for 3 weeks)
Number of subjects: 35
Study 12241530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 3 weeks)
Number of subjects: 35
Study 10404801 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg orally once daily for 6 months (group 1)
Number of subjects: 18
Study 10404801 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 18
Study 8552122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg pergolide
Number of subjects: 12
Study 8552122 — intervention group
Group type: COMPARATOR
Intervention: 10 mg bromocriptine
Number of subjects: 12
Study 31359368 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (60 units/day)
Number of subjects: 0
Study 31359368 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (< 60 units/day)
Number of subjects: 0
Study 31359368 — intervention group
Group type: COMPARATOR
Intervention: iGlar (60 units/day)
Number of subjects: 0
Study 31359368 — intervention group
Group type: COMPARATOR
Intervention: iGlar (< 60 units/day)
Number of subjects: 0
Study 31359368 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (60 or < 60 units/day)
Number of subjects: 0
Study 27987224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile cooperation intervention (mobile application‐assisted cooperation and training in the functions of the mobile application)
Number of subjects: 0
Study 27987224 — intervention group
Group type: COMPARATOR
Intervention: Standard cooperation (control group)
Number of subjects: 0
Study 25877711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium eye drops, twice a day for three days before surgery and one day after surgery
Number of subjects: 64
Study 25877711 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine eye drops, four times a day for three days before surgery and one day after surgery
Number of subjects: 64
Study 25877711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium eye drops
Number of subjects: 64
Study 25877711 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine eye drops
Number of subjects: 64
Study 23636449 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 420
Study 23636449 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg/day
Number of subjects: 420
Study 23636449 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant prophylaxis
Number of subjects: 420
Study 23636449 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (both LMWH and Warfarin)
Number of subjects: 420
Study 22012500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitchback exercise
Number of subjects: 0
Study 22012500 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF D2 pattern with tubing
Number of subjects: 0
Study 22012500 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-up plus exercise
Number of subjects: 0
Study 22012500 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide board exercise
Number of subjects: 0
Study 18722818 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo
Number of subjects: 8
Study 18722818 — intervention group
Group type: COMPARATOR
Intervention: Usual graded activity
Number of subjects: 8
Study 16415628 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention program combining pelvic floor muscle exercise with bladder training (4 weeks, once a week)
Number of subjects: 60
Study 16415628 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention program
Number of subjects: 60
Study 16415628 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment (9th week)
Number of subjects: 60
Study 16415628 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment
Number of subjects: 60
Study 16415628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 12215470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring (hyperbaric index)
Number of subjects: 403
Study 12215470 — intervention group
Group type: COMPARATOR
Intervention: Office blood pressure measurements
Number of subjects: 403
Study 12215470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 403
Study 12215470 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnancies
Number of subjects: 403
Study 10473014 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-support (VS), N = 52
Number of subjects: 106
Study 10473014 — intervention group
Group type: COMPARATOR
Intervention: Office-based (OB), N = 54
Number of subjects: 106
Study 8904740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnanolone (two different formulations)
Number of subjects: 18
Study 8904740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not administered in this study)
Number of subjects: 18
Study 1680325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridazolol
Number of subjects: 12
Study 1680325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6406699 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% zinc oxide ointment
Number of subjects: 9
Study 6406699 — intervention group
Group type: COMPARATOR
Intervention: Plain petrolatum ointment
Number of subjects: 9
Study 30772148 — intervention group
Group type: EXPERIMENTAL
Intervention: Green space intervention
Number of subjects: 931
Study 30772148 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional playground)
Number of subjects: 931
Study 30400588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei (LP)
Number of subjects: 160
Study 30400588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum (LF)
Number of subjects: 160
Study 30400588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei (LP) + Lactobacillus fermentum (LF)
Number of subjects: 160
Study 26718808 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg oral misoprostol
Number of subjects: 1820
Study 26718808 — intervention group
Group type: COMPARATOR
Intervention: 10 IU oxytocin in Uniject (intramuscular)
Number of subjects: 1820
Study 25098777 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose US group (0.5 ml/kg LA)
Number of subjects: 100
Study 25098777 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% reduced dose LA (0.35 ml/kg)
Number of subjects: 100
Study 25098777 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduced dose LA (0.25 ml/kg)
Number of subjects: 100
Study 25098777 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% reduced dose LA (0.15 ml/kg)
Number of subjects: 100
Study 25098777 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation alone group (0.5 ml/kg LA)
Number of subjects: 100
Study 25098777 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (FD, 30, NS)
Number of subjects: 100
Study 25098777 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose group
Number of subjects: 100
Study 22448716 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral aortic valve implantation (TAVI)
Number of subjects: 30
Study 18706549 — intervention group
Group type: EXPERIMENTAL
Intervention: Long letrozole therapy (n = 108; 219 cycles)
Number of subjects: 218
Study 18706549 — intervention group
Group type: COMPARATOR
Intervention: Short letrozole therapy (n = 110; 225 cycles)
Number of subjects: 218
Study 18706549 — intervention group
Group type: EXPERIMENTAL
Intervention: Long letrozole therapy
Number of subjects: 218
Study 18706549 — intervention group
Group type: COMPARATOR
Intervention: Short letrozole therapy
Number of subjects: 218
Study 19001352 — intervention group
Group type: EXPERIMENTAL
Intervention: GIST (group, individual, and staff therapy)
Number of subjects: 25
Study 19001352 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 25
Study 16041534 — intervention group
Group type: EXPERIMENTAL
Intervention: biperiden (2 mg)
Number of subjects: 16
Study 16041534 — intervention group
Group type: EXPERIMENTAL
Intervention: rivastigmine (3 mg)
Number of subjects: 16
Study 16041534 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 11828049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH) care
Number of subjects: 60
Study 11828049 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 60
Study 10407599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg monthly doses)
Number of subjects: 100
Study 7574954 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (37 degrees C)
Number of subjects: 101
Study 7574954 — intervention group
Group type: COMPARATOR
Intervention: Mild hypothermic blood cardioplegia (28 degrees to 29 degrees C)
Number of subjects: 101
Study 2147752 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Number of subjects: 184
Study 2147752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg twice daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Number of subjects: 184
Study 2147752 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 184
Study 2147752 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 184
Study 7438715 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine enkephalin analogue DAMME infusion
Number of subjects: 0
Study 30977273 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg NAC syrup, orally once daily at night for 7 consecutive days
Number of subjects: 57
Study 30977273 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered similarly to NAC
Number of subjects: 57
Study 30977273 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC and Placebo
Number of subjects: 57